MedJobScout :: Health :: Medicine :: Medical Specialties :: Hematology (7)

All Hematology-Oncology Jobs

Permanent Hematology-Oncology Job in $350,000 in Oklahoma with Partnership Oklahoma with CompHealth Inc
Job 915111 Solo Oncologist in Oklahoma seeks another to join him. Excellent opportunity in a family-friendly area. Small town practice Begin seeing 12+ patients per day Build the practice to your desired
Permanent Hematology-Oncology Job in Growing Group Seeking Hem or Med Onc for an "All American" City in California California with CompHealth Inc
Job 914692 A recognized cancer center in one of the largest cities in California is seeking an Oncologist for their group. Partnership track optional. Golf, recreation, theatre, museums, arts and culture,
Permanent Hematology-Oncology Job in Join a Great Multispecialty Group in a Family Friendly Community Ohio with CompHealth Inc
Job 915752 Admit to 1 hospital Great schools Partnership track Competitive salary Starting bonus and loan forgiveness Clinic attached to the hospital CompHealth offers thousands of physician jobs

Current Opinion in Hematology - Current Table Of Contents

Editorial introductions.
Page: ivDOI: 10.1097/MOH.0b013e328316c0b9
New advances in hematopoietic cell transplantation.
Page: 549DOI: 10.1097/MOH.0b013e328311891fAuthors: Petersdorf, Effie W; Hansen, John A
Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?.
Page: 555DOI: 10.1097/MOH.0b013e32831188f5Authors: Adkins, Douglas R; DiPersio, John F

Hematological Oncology

Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Sabine Schreck, Daniela Friebel, Maike Buettner, Luitpold Distel, Gerhard Grabenbauer, Lawrence S. Young, Gerald Niedobitek Wed, 15 Oct 2008 03:59:00 -0000
Classical Hodgkin Lymphoma (cHL) is morphologically characterized by a small number of tumour cells, Hodgkin and Reed-Sternberg (HRS) cells, surrounded by numerous tumour-infiltrating lymphocytes (TIL). The functional role of these TIL is still controversial. While generally considered to represent an anti-tumour immune response, TIL in cHL might result from the profoundly deregulated immunity of cHL patients. Eighty-seven cases of cHL were available to evaluate the prognostical significance of tumour-infiltrating cytotoxic T lymphocytes (CTL), T helper 1 (Th1) cells, T helper 2 (Th2) cells and regulatory T cells (Treg). We confirm that in cHL the microenvironment is dominated by Th2 cells and Treg and show that large numbers of Th2 cells are associated with significantly improved disease-free survival (p = 0.021) and event-free survival (p = 0.012). Furthermore, a high ratio of Treg over Th2 cells resulted in a significantly shortened disease-free survival (p = 0.025). These observations suggest that Treg may exert inhibitory effects on anti-tumour immune responses mediated through Th2 cells and that Th2 cells may be more important for effective anti-tumour immunity than anticipated. Copyright © 2008 John Wiley & Sons, Ltd.
Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/67gallium scintigraphy abnormality
Akira Kitanaka, Yoshitsugu Kubota, Osamu Imataki, Hiroaki Ohnishi, Tetsuya Fukumoto, Kazutaka Kurokohchi, Terukazu Tanaka Fri, 26 Sep 2008 03:51:00 -0000
Intravascular large B-cell lymphoma (IVLBCL) is a rare lymphoma characterized by the presence of large tumour cells within the blood vessels. It has been considered that IVLBCL is a highly malignant disease with poor prognosis. However, it has been shown that a therapeutic effect resembling that of conventional B-cell lymphomas may be obtained with the application of systemic chemotherapy at the early stage of this disease. Although involvement in the lung is often detected at autopsy, early diagnosis is quite difficult. In this report, we present a case of IVLBCL with pulmonary involvement where 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) was useful in the early diagnosis. Neither computed tomography (CT) nor 67gallium scintigraphy could reveal the presence of disease in the lung. Histological evidence of IVLBCL was obtained by TBLB after FDG uptake in the lung was confirmed by FDG-PET. The patient exhibited a good response to the subsequent combination chemotherapy. We propose that FDG-PET is a powerful tool for the early diagnosis of IVLBCL with pulmonary involvement, if the possibility of this disease presents in the patient with respiratory symptoms without abnormal findings by CT and 67gallium scintigraphy. Copyright © 2008 John Wiley & Sons, Ltd.
Molecular targeting of the PKC-[beta] inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression
Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza, Monica Civallero, Jessika Bertacchini, Giorgio Lambertenghi Deliliers, Stefano Sacchi, Luigia Lombardi, Antonino Neri Mon, 01 Sep 2008 03:59:00 -0000
The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM. Copyright © 2008 John Wiley & Sons, Ltd.

Annals of Hematology

Effects of chloroquine treatment on circulating erythropoietin and inflammatory cytokines in acute Plasmodium falciparum malaria
Tue, 25 Nov 2008 06:48:43 -0000
Abstract  Anemia is a common and serious complication of malaria due to Plasmodium falciparum infection, a major health problem in tropical areas. Herein, the relation was investigated between the levels of circulating erythropoietin (EPO) and immunomodulatory cytokines in response to chloroquine treatment. Thirty-seven healthy control subjects and 40 patients with acute P. falciparum infection were included in the study. All subjects were adult male Sudanese. Blood samples were collected before chloroquine administration (25 mg/kg body weight, orally on three consecutive days) and 3 and 30 days after start of the therapy. Measurements included routine hematological parameters and the concentrations of immunoreactive EPO, tumor necrosis factor-α (TNF-α), interleukin 1α (IL-1), IL-6, and interferon γ (INF-γ). Chloroquine treatment led to a decrease in EPO levels in the control subjects but an increase in malaria patients at day 30. The latter was likely due to the anti-inflammatory action of the drug because INF-γ, IL-1, and IL-6 concentrations declined on chloroquine treatment. Based on these findings, we propose that an impaired EPO production in association with a prolonged elevation of certain inflammatory cytokines can contribute to the anemia in some malaria patients which can be reversed by chloroquine therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0636-zAuthors Adil Ballal, University of Khartoum Department of Physiology Khartoum SudanAmal Saeed, University of Khartoum Department of Physiology Khartoum SudanPatricia Rouina, University of Luebeck Institute of Physiology Ratzeburger Allee 160 23538 Lubeck GermanyWolfgang Jelkmann, University of Luebeck Institute of Physiology Ratzeburger Allee 160 23538 Lubeck Germany Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age
Sun, 23 Nov 2008 06:46:40 -0000
Abstract  Increasing recipient age is a well-known risk factor for graft-versus-host disease (GVHD) and treatment-related mortality (TRM) and has a negative impact on allogeneic hematopoietic stem cell transplantation. Since the incidence of severe GVHD after cord blood transplantation (CBT) is lower than that after transplants using bone marrow or mobilized peripheral blood grafts from adult cells, we should expect better outcomes from CBT in older patients. To evaluate the feasibility and efficacy of myeloablative unrelated CBT in patients aged between 50 and 55 years, we performed a retrospective comparison of 100 patients with acute leukemia who received cord blood grafts at our institution. Nineteen older patients (median age, 52; range, 50–55) and 81 younger patients (median, 36; range, 16–49) received a myeloablative conditioning regimen including 12 Gy of total body irradiation and chemotherapy. GVHD prophylaxis included cyclosporine with (n = 96) or without (n = 4) methotrexate. There were no significant differences in the incidences of grades II to IV acute GVHD, extensive-type chronic GVHD, TRM, and the probability of overall and disease-free survival between these groups. These results suggest that, in patients with acute leukemia, myeloablative CBT might be as safe and effective in patients aged between 50 and 55 years as in younger patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0641-2Authors Takaaki Konuma, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanSatoshi Takahashi, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanJun Ooi, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanAkira Tomonari, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanNobuhiro Tsukada, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanSeiko Kato, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanAki Sato, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanFumihiko Monma, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanSenji Kasahara, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanTokiko Nagamura-Inoue, The University of Tokyo Department of Transfusion Medicine, The Institute of Medical Science Tokyo JapanKaoru Uchimaru, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanTohru Iseki, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanArinobu Tojo, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 JapanTakuhiro Yamaguchi, The University of Tokyo Department of Clinical Trial Data Management Tokyo JapanShigetaka Asano, The University of Tokyo Department of Hematology/Oncology, The Institute of Medical Science 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639 Japan Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis
Sun, 23 Nov 2008 06:46:40 -0000
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-008-0640-3Authors Jin Lee, University of Pittsburgh Medical Center Arnold Palmer Pavilion at Mountain View Medical Park, 200 Village Drive Greensburg PA 15601 USA Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555

American Journal of Hematology

Familial myeloma and monoclonal gammopathy: A report of eight African American families
Maneesh Jain, Joao Ascensao, Geraldine P. Schechter Wed, 29 Oct 2008 22:07:00 -0000
Previous descriptions of familial myeloma have been mainly of Caucasian families. We report here eight African American families with familial multiple myeloma and monoclonal gammopathy identified over a 30 year period. Six patients with multiple myeloma (MM) and two with monoclonal gammopathy of unknown significance (MGUS) reported a family history of MM or had family members with MGUS found on screening. A pedigree compiled for each family included a history of other cancers. In the eight families, 21 of 58 first degree relatives had a plasma cell dyscrasia including 12 MM, eight MGUS, and one amyloidosis patient(s). The age of the MM patients ranged from 50 to 78 years (median 61 years). Four families had two members with MM, including one mother-son and three sibling pairs. Two MM families each had two additional first degree relatives with MGUS, with three generations involved in one family. Anticipation was suggested in two families with parent-child pairs with monoclonal gammopathy. The eight pedigrees had 66 members, 21 of whom had a diagnosis of cancer, including non-Hodgkin lymphoma and Hodgkin disease, or a clonal myeloproliferative disorder other than MM. Although the mode of genetic transmission and anticipation cannot be confirmed due to the small sample size, the increased number of MM and MGUS family members suggests underlying genetic susceptibility factors for plasma cell dyscrasias and possibly for other cancers in these families. Am. J. Hematol., 2009. © 2008 Wiley-Liss, Inc.
Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
David P. Steensma Tue, 28 Oct 2008 18:26:00 -0000
No abstract.
Positive impact of maintaining minimal caloric intake above 1.0 × basal energy expenditure on the nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation
Shigeo Fuji, Sung-Won Kim, Takahiro Fukuda, Shigemi Kamiya, Setsuko Kuwahara, Yoichi Takaue Wed, 08 Oct 2008 16:52:00 -0000
No abstract.

Pediatric Hematology and Oncology: Articles recently published in

EXPRESSION OF MATRIX METALLOPROTEINASE-9 (MMP-9) AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE (TIMP-1) IN TISSUES WITH A DIAGNOSIS OF CHILDHOOD LYMPHOMA
Birgen, DilekYüksek, NazmiyeŞahin, GürsesBozkurt, CeyhunErtem, UlyaOksal, Ayşegül Mon, 01 Sep 2008 00:00:00 -0000

EVALUATION OF GLUCOSE HOMEOSTASIS IN TRANSFUSION-DEPENDENT THALASSEMIC PATIENTS
Öçal, GönülErtem, MehmetEngiz, ÖzlemAdıyaman, PelinGözdaşoğlu, SevgiBerberoğlu, MerihUysal, ZümrütÇıtak, Funda ErkasarŞıklar, Zeynepİleri, Talia Mon, 01 Sep 2008 00:00:00 -0000

DENTAL HEALTH INDICES OF LONG-TERM CHILDHOOD CANCER SURVIVORS WHO HAD ORAL SUPERVISION DURING TREATMENT: A Case-Control Study
Sevinir, BetülÇubukçu, Çiğdem Elbek Mon, 01 Sep 2008 00:00:00 -0000


Subscribe to Hematology RSS feed